Workflow
华丰科技: 申万宏源证券承销保荐有限责任公司关于四川华丰科技股份有限公司部分募集资金投资项目结项并将节余募集资金永久补充流动资金及部分募集资金投资项目延期的核查意见

Summary of Key Points Core Viewpoint - The company has completed certain fundraising investment projects and plans to permanently supplement its working capital with the remaining funds, while also postponing some investment projects [1][9]. Fundraising Overview - The company raised a total of RMB 640.32 million through its initial public offering, with a net amount of RMB 571.48 million after deducting underwriting fees and other expenses [1]. - The funds have been deposited into a dedicated account, and a tripartite supervision agreement has been signed with the underwriter and the bank [1]. Fund Usage and Project Completion - The company has approved the use of excess funds amounting to RMB 67.70 million for the construction of a new high-speed module production line, with a total project investment of RMB 147.20 million [2]. - As of May 31, 2025, the cumulative investment in the fundraising projects is as follows: total investment of RMB 650.98 million, with RMB 571.48 million planned from fundraising, and an 80.63% completion rate [2]. Project Completion and Surplus Funds - The projects "Mianyang Industrial Base Expansion" and "High-Speed Module Production Line" have reached a usable state, allowing for their completion [4]. - The surplus funds from these projects, amounting to RMB 37.99 million, will be transferred to the company's general bank account to permanently supplement working capital [5]. Project Delay - The "R&D Innovation Center Upgrade" project has been postponed to April 30, 2026, to ensure alignment with the company's long-term strategic goals [6][8]. - The delay is based on a careful assessment of the project's progress and funding usage, ensuring that the investment content and total amount remain unchanged [7][8]. Approval Process - The board of directors and the supervisory board have approved the completion of certain fundraising projects and the use of surplus funds, confirming that these actions align with regulatory requirements and do not harm shareholder interests [8][9].